Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.67 |
| ▸ | THRA | P10827 | 9/20 | 0.67 |
| ▸ | PCNA | P12004 | 8/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.67 |
| ▸ | PPARG | P37231 | 2/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.67 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008454 | 0.83 | PCNA (0.61) | THRBTHRAPCNALMNAPOLB | |
| SCHEMBL24407712 | 0.83 | THRB (0.54) | THRBTHRAPCNALMNAPOLB | |
| SCHEMBL7526093 | 0.83 | THRB (0.72) | THRBTHRA | |
| SCHEMBL9522943 | 0.81 | THRB (0.64) | THRBTHRAPCNALMNAPOLB | |
| SCHEMBL6720943 | 0.81 | TPMT (0.50) | THRBTHRAPCNALMNAPOLB | |
| Tiratricol SCHEMBL30161572 | 0.80 | THRB (1.00) | THRBTHRAPCNALMNAPOLB | |
| Tiratricol SCHEMBL25149 | 0.80 | THRB (1.00) | THRBTHRAPCNALMNAPOLB | |
| Tiratricol SCHEMBL743426 | 0.80 | THRB (1.00) | THRBTHRAPCNALMNAPOLB | |
| SCHEMBL7086473 | 0.79 | THRB (0.61) | THRBTHRAPCNALMNAPOLB | |
| Tiratricol SCHEMBL2671904 | 0.79 | THRB (0.97) | THRBTHRAPCNALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | NANOPHARMACEUTICALS, LLC | 2015-01-29 | — | — | US | disclosed |
| US-8859539-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2014-10-14 | — | — | US | disclosed |
| EP-0204523-B1 | GLUCOSE-6-PHOSPHATE DEHYDROGENASE CONJUGATES, THEIR PREPARATION AND USE | SYNTEX (U.S.A.) INC. (US) | 1992-02-26 | — | — | EP | disclosed |
| US-4847195-A | IMMUNOASSAY | SYNTEX (U.S.A.) INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0204523-A2 | Glucose-6-phosphate dehydrogenase conjugates, their preparation and use | SYNTEX (U.S.A.) INC. (US) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | THRB 4/4885THRA 2/4885PCNA 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.